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Abstract  
Background/Aims: Large epidemiological prospective studies represent an important 
opportunity for investigating risk factors for rare diseases such as Parkinson’s disease 
(PD). Here we describe the procedures we used for ascertaining PD cases in the 
European Prospective Investigation into Cancer and Nutrition (EPIC). 
Methods: A three-phase procedure was used: elaboration of a NeuroEPIC4PD 
template for clinical data collection, identification all potential PD cases via record 
linkage, and validation of the diagnosis through clinical record revision, in a 
population of 220,494 subjects recruited in 7 European countries. All cases were 
labelled with a NeuroEPIC4PD diagnoses of “definite”, “very likely”, “probable”, or 
“possible” PD. 
Results: A total of 881 PD cases were identified, over 2,741,780 person/years follow-
up (199 definite, 275 very likely, 146 probable, and 261 possible). Of these, 734 were 
incident cases. Their mean age at diagnosis was 67.9 years (SD 9.2), and 458 (52.0%) 
were men. Bradykinesia was the most frequent presenting motor sign (76.5%). 
Tremor-dominant and akinetic rigid forms of PD were the most common types of PD. 
A total of 289 (32.8%) were dead at the time of last follow-up. 
Conclusions: this exercise proved that it is feasible to ascertain PD in large population-
based cohort studies, and offer a potential framework to be replicated in similar 
studies. 
 
Keywords: Parkinson’s disease, cohort study, case ascertainment, record linkage, 
validation, EPIC, incidence.
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Introduction  
Parkinson's disease (PD) is the second most common neurodegenerative disorder 
after Alzheimer's disease. PD is characterised by motor dysfunction, such as 
bradykinesia, resting tremor, rigidity and postural instability, but also affects the 
autonomic nervous system, cognition, and a range of other non-motor functions (1). 
The incidence of the disease rises with age, peaking at 119.5 per 100,000 person 
years in the seventieth decade, with a lifetime risk of developing the disease of 1.5-3% 
(2-5). The median age of onset is in the late 60s (4-6) and the mean duration of the 
disease from diagnosis to death is 15 years (3). Because of ageing of western 
populations, an increase in incidence can be anticipated.  
Large established prospective population studies offer an important opportunity for 
investigating the role of risk factors for rarer diseases such as PD, with relatively small 
additional effort for ascertaining cases. In particular, data coming from such studies 
can shed light on potential mechanisms of action of factors known to be negatively 
associated with PD (i.e. cigarette smoking) using modern advanced epidemiological 
techniques (such as Mendelian randomisation). To date PD has been investigated in 
relatively small cohorts (7-17) (with the numbers of PD cases ranging from 41 (15) to 
656 (16)) or using self-reported diagnosis only (17). Cohort studies with large sample 
sizes and well characterised and validated case definitions have a high degree of 
power for detecting weak associations with environmental factors.  
The aim of this study was to describe the procedures used to ascertain PD cases in 
the EPIC cohort in order to enable investigators to prospectively assess the 
association between pre-diagnostic risk factors and the incidence of the disease: the 
NeuroEPIC4PD study. The methods used in this study are expected to be 
generalizable to other cohorts.  
 
 
Materials and Methods  
The EPIC study  
The European Prospective Investigation into Cancer and Nutrition (EPIC) study is a 
large, well established, multicentre cohort study on-going in ten Western European 
countries(18). At baseline, information on lifestyle (education, occupation, lifetime 
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tobacco and alcohol consumption, physical activity, oral contraceptive and hormone 
replacement therapy) menstrual and reproductive history, and past medical history 
was collected through a questionnaire. Anthropometric assessments and blood 
pressure were measured in a standardised way (18). Dietary intake was assessed 
through self-administered quantitative dietary questionnaires and a 24-hour dietary 
recall questionnaire (19). EPIC was originally designed to investigate the role of 
nutrition in cancer aetiology, but it has also demonstrated its value for investigating 
other medical conditions such as cardiovascular diseases (20), and diabetes (21).  
 
The NeuroEPIC4PD population 
The NeuroEPIC4PD study is based on an source population of 220,494 subjects 
recruited in Sweden (Umea and Malmo), UK (Cambridge), Netherlands (Utrecht), 
Germany (Heidelberg), Spain (Navarra, San Sebastian, and Murcia), Italy (Turin, 
Varese, Florence and Naples), and Greece from the general population residing in 
defined geographical areas between 1992 and 2002 within the EPIC study (18). 
Exception was the Utrecht-Prospect cohort which was based on breast cancer 
screening participants (18). The Naples and Utrecht-Prospect cohorts were restricted 
to women, whereas all other cohorts included both sexes. In EPIC, follow-up for 
mortality and specific causes of death is carried out actively or through linkage with 
mortality registries at regional and national levels (18). To date, follow-up is 98.5% 
complete. 
 
Expected PD cases 
Numbers of expected PD cases were calculated in order to compare completeness of 
procedures used in different centres, and to estimate the workload of phase III in 
each centre. They were estimated applying sex- and age-specific incidence rates 
coming from weighted averages of population-based studies investigating PD 
incidence (4, 22-27).  Sex- and age-specific cumulative incidence rates were 
calculated over the sex- and centre-specific follow-up periods in each EPIC sub-cohort 
resulting in estimates of expected cases during the current follow-up.  
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Case ascertainment methods  
Case ascertainment was organised in three phases: in Phase I the NeuroEPIC4PD 
template for clinical data collection - including the NeuroEPIC4PD label to be 
attached to each diagnosis - was elaborated by a group of experienced neurologists 
and epidemiologists. During Phase II, each centre identified potential cases through 
record linkage with one or more local sources of information. Clinical records of 
potential cases were then reviewed by experts in movement disorders and given a 
final diagnosis with a NeuroEPIC4PD label, during Phase III (Online Figure 1). The 
three phases will be described more in detail below. 
 
Phase I: NeuroEPIC4PD template for clinical data collection  
The first NeuroEPIC meeting took place on November 29th 2010. During the meeting 
the strategy for PD case ascertainment was discussed in detail by a group of 
neurologists and epidemiologists. The final outcome was the elaboration of the 
template for clinical data collection (Appendix 1) and the definition of the 
NeuroEPIC4PD label to be given to every case ascertained in EPIC. The template 
included sections on general information, diagnostic criteria according to the UK 
Brain Bank(28), additional clinical data, medication, surgical treatment, autopsy, 
source of information and quality of data, and final diagnosis. Possible final diagnoses 
included: PD, Multiple System Atrophy (MSA), progressive supranuclear palsy (PSP), 
vascular parkinsonism (VD), dementia with Lewy bodies (LBD), essential tremor (ET), 
Parkinson’s disease with essential tremor (PDET), unclassifiable parkinsonism (UP), 
and other diagnosis.  
Each diagnosis was labelled with a NeuroEPIC4PD label, which was based on a 
matrix combining two variables: the amount and quality of data available, and the 
degree of confidence of the neurologist expert in movement disorders reviewing the 
evidence (Online Figure 2, Appendix 1). The amount and quality of data available 
could be rated as “poor”, “good” or “excellent”, where “excellent” data was defined as 
a complete set of clinical data able to give a clear picture of the case (including 
detailed neurological examinations), with scattered non-essential missing 
information; “good” data was defined as a set of data giving a fairly complete idea of 
the case with scattered essential information missing; “poor” data was defined as an 
incomplete set of data, with much essential information missing. The degree of 
confidence of the neurologist could be rated as “high”, “medium”, or “low” on the 
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basis of his/her final judgment of the clinical history of the single case. It was stated 
very clearly that this judgement was independent of the amount of information 
available (a neurologist could have a high degree of confidence despite very poor 
information, or a low degree of confidence despite very detailed information). 
Diagnoses were defined as “definite” only when the degree of confidence of the 
neurologist was high and data quality excellent; diagnoses were defined as “very 
likely” when the degree of confidence of the neurologist was high, but data quality 
was either good or poor; and defined as “probable” when the degree of confidence 
of the neurologist was medium and data quality was either excellent or good; finally, 
diagnoses were defined as “possible” in all remaining cases.  
 
Phase II: Potential PD cases identification 
Potential PD cases were identified by centre-specific strategies, in order to optimise 
local sources of data. The general principle was to increase sensitivity as much as 
possible in order to minimise the number of false negatives given that the 
subsequent clinical record review would maximise specificity. In addition, patterns of 
possible referrals pathways for PD cases in each centre were collected in order to 
evaluate the adequacy of the sources of information used. Specific sources of 
information by centre used in Phase II are shown in Online Figure 1; details of the 
procedures can be found in Appendix 2.  
 
Phase III – Case validation and collection of additional clinical data 
For all potential cases identified in Phase II, clinical records were searched for and 
reviewed by a neurologist expert in movement disorders. For each subject for whom 
at least some information was available, a clinical data form was filled in (Appendix 
1). Each potential case was then attached a final diagnosis (PD, MSA, PSP, VD, LBD, 
ET, PDET, UP, and other diagnosis) and labelled with a NeuroEPIC4PD labels (Online 
Figure 2). 
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Results  
The source population used for the NeuroEPIC4PD study includes 220,494 subjects 
recruited in 13 EPIC centres across 7 European countries (Online Table 1). Mean age 
of the population at recruitment was 53.1 years (SD 10.0). The recruitment 
framework oversampled women by design, resulting in a total of 83,320 (37.8%) men 
recruited, exceptions being Utrecht and Naples which recruited women only. The 
entire population was followed up for a mean of 12.4 years (SD 2.8) generating a 
total 2,741,780 person years. Of the entire cohort, 19,473 subjects (8.8%) died 
according to the updated vital status by the last follow-up visit.   
Applying the sex- and age-specific incidence rates of PD derived from population 
based studies, a total of 309 PD cases were expected over the current follow-up 
period. These were distributed according to figures shown in Table 1.  
 
Phase II: Potential PD cases identification 
A total of 1,723 potential PD cases were identified across all centres (Online Figure 3 
and Table 1). Overall potential cases were about 5.6 times more than expected cases. 
In Utrecht and Varese potential cases were very close to expected. In Murcia and 
Turin potential cases were more than ten times higher than expected; while in the 
remaining centres they were between about 250 and 650% with the exception of 
Cambridge where they were 800%. Differences are likely due to differences in 
sources of information used by centres.   
 
Phase III – Case validation and collection of additional clinical data 
Additional clinical information was collected using the NeuroEPIC4PD template in 
1,336 out of 1,723 potential cases (77.5%) ; few centres (Umea, Navarra, Murcia, 
Varese, Naples, and Greece) were able to verify all potential cases; others (Malmo, 
San Sebastian, and Florence) could verify the great majority of potential cases (87.7 to 
98.0%); and other centres  (Utrecht, Cambridge, Heidelberg, and Turin) only a smaller 
proportion of potential cases (47.5 to 66.9%) (Table 1, Figure 1). The variation in 
these proportions is mainly due to ability of retrieving clinical records of potential 
cases; and to the extent to which the criteria used in phase II had a high sensitivity 
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(including a higher proportion of false positive who would not have a clinical record 
for PD artificially inflating the number of potential cases). 
On the basis of the clinical information available, 881 PD cases (65.9%), 230 
parkinsonian-related disorders (17.2%), and 225 unrelated conditions (16.8%) were 
identified (Table 1). Cases who received a diagnosis after the date of recruitment 
were defined as incident cases (N=734). Out of the 881 PD cases, 199 were labelled 
as definite PD cases (22.6%), 275 as very likely (31.2%), 146 as probable (29.6%), and 
261 as possible (29.6%). Among the parkinsonian-related disorders, 26 MSA, 22 PSP, 
34 VP, 34 LBD, 30 ET, and 9 PDET were identified. Additionally, 75 cases (5.6% of the 
total) were defined as having UP (Online Table 2). 
PD cases are more than double of those originally expected. All centres have 
ascertained more than expected cases a part from Utrecht and Varese where about 
half of expected cases has been ascertained. For all other centres, proportion range 
from 200% in Florence to 757% in Murcia (Table 1, Figure 1). In each country, the 
shape of the age- and sex-specific cumulative incidence peaks at 70-79 years with 
exception of Spain and Germany where it peaks at 60-69 years in both men and 
women (Figure 2-3). A part from Netherlands, differences between observed and 
expected curves are mainly due to age-truncation of the cohorts, in fact in all 
countries, the incidence rates at older ages are much lower than expected, but this 
may simply reflect the age-composition of the EPIC cohort (Online Table 1).  
General and clinical characteristics of PD patients are described in Table 2. Despite 
women outnumbering men in this study, there is slight predominance of men among 
PD patients, except for the definite PD category. Individuals with PD were recruited 
when they were on average 61.9 years of age (SD 8.2) they noticed their first motor 
symptoms at a mean age of 66.8 years (SD 8.3), and were diagnosed on average one 
year later, i.e. at 67.9 years (SD 9.2). Relaxing criteria of certainty of the diagnosis, the 
gap between first motor symptom and diagnosis shortens. Bradykinesia is the most 
frequent cardinal sign (present in 76.5% of all PD patients). The prevalence of 
bradykinesia, resting tremor, and rigidity increases the certainty of the diagnosis; this 
is not observable for postural instability which remains roughly constant across 
categories, and slightly more frequent among probable cases (Table 2). Tremor-
dominant and akinetic rigid forms are the most common types of PD across all 
NeuroEPIC4PD labels and their relative difference decreases, decreasing the certainty 
of the diagnosis (Figure 2). Levodopa and dopamine agonists are the most common 
drugs taken by these PD patients, and all drugs are proportionally taken more 
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frequently by patients with a more certain diagnosis. A total of 16 PD patients had a 
surgical treatment with deep brain stimulation. A total of 289 (32.8% of entire 
sample) were dead at the time of last follow-up within the NeuroEPIC4PD study 
(Table 2). 
 
 
Discussion 
This exercise proved that it is feasible to ascertain PD cases in large population-based 
multicentre studies. Maximising the local expertise and sources of information, and 
through involving epidemiologists and neurologists in the project, we were able to 
ascertain a considerable number of cases, labelled with a different degree of 
certainty, which will allow us to exploit the invaluable resource of a prospective study 
in investigating risk factors for this relatively rare neurodegenerative disorder. 
Using a three-phase approach, we were able to optimise our search by maximising 
sensitivity in phase II (thus minimising the false negative rate), and specificity in phase 
III (therefore minimising the false positive rate). The only limit to this approach 
remains the proportion of potential cases which could not be ascertained, thus 
introducing potential false negatives in our sample. However, in the present case this 
proportion was low and only seen in few centres for practical reasons (Utrecht and 
Heidelberg); in Cambridge and Turin this is more likely due to having relaxed criteria 
for identifying potential cases in phase II; in fact in both centres, the number of 
ascertained cases is well above the number of expected cases (Figure 1). Also, it is 
important to note that in the context of studying a rare disease in a large cohort 
study it is of greater relevance to minimise false positive diagnoses which may bias 
results towards the null, than to minimise false negatives which will be diluted in a 
very large set of non-cases making their impact negligible.  
The finding of a higher number of cases than expected may be due to two reasons: 
firstly, expected cases were calculated on the follow-up period for which data had 
been centralised in EPIC, while in each centre, case ascertainment was conducted on 
a longer period of follow-up, counting the follow-up time which was available locally. 
Secondly, we expect more cases according to the healthy cohort effect given that 
cigarette smoking is inversely associated with PD(29): if less smokers than in the 
general population enrol in epidemiological studies (as occurred in EPIC), this would 
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lead to a less than expected number of smoking-related diseases, but to a higher 
number of PD cases.  
Finally, the large differences between potential and ascertained cases reflect the 
different methods used in phase I.   When more specific methods were used (i.e. 
Umea, Heidelberg, Greece), it was more likely that a potential case was a true case. 
Overall, the plots of age-specific incident rates by country confirm that the 
procedures used were appropriate for the population observed, and that the quality 
of our case ascertainment procedures was quite high. Moreover, the NeuroEPIC4PD 
label is able to effectively discriminate between a high and low certainty of diagnosis: 
the NeuroEPIC4PD labelling was studied in order to optimise the trade-off between 
power and specificity. By including possible cases, the power for detecting 
associations with potential risk/protective factors will be maximised; the presence of 
the label, however, will allow sensitivity analyses on those cases with a higher degree 
of certainty only.  
Clinical characteristics of PD cases using the NeuroEPIC4PD label, reflect the fact that 
the label is also calculated on the basis of the amount and quality of data available. 
The crude mortality among PD cases is higher than in the rest of the population, a 
part from the definite PD. Age at diagnosis seems to be inversely correlated with 
degree of certainty of diagnosis. This may reflect reduced specificity of symptoms 
such as bradykinesia, rigidity and postural instability, which are more common (less 
sensitive) and multifactorial in origin (arthritis, cerebrovascular diseases, etc.), 
especially in the aged. 
The results of this exercise are expected to inform case ascertainment of PD in other 
cohort studies. As can easily be deduced by the complexity and heterogeneity of the 
procedures used, maximising the local resources and sources of information is of 
paramount importance in this exercise. The epidemiological effort is to harmonise 
data coming from such different sources and build a method which allows for the 
trade-off between power and specificity that studies of this nature encounter. 
This type of study should coordinate closely with other population-based PD cohort 
studies, such as the CamPaIGN study (30). These can potentially produce 
complementary information for investigating the complex interactions of risk factors 
underlying PD. While cohort studies can shed light on the role of potential risk factors 
(and molecular markers) for developing PD, the patient cohorts can investigate the 
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role of the same risk factors (and the same biological markers) on PD survival, 
complementing the causal inference process.  
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Table 1: Total population, expected PD cases, potential PD cases, and final diagnoses of the subjects recruited in the centres participating in the 
NeuroEPIC4PD study 
 
 
 
Centre Population Expected 
PD cases  
Potential cases 
(phase II) 
Cases reviewed 
in phase III (% of 
potential)  
Incident PD Prevalent PD Total PD Parkinsonian
-related 
disorders 
Other 
diseases 
Umea (SW) 25,717 23- 62 62 (100.0) 55 1 56 6 0 
Malmo (SW) 28,097 63 305 299 (98.0) 140 17 166* 79 54 
Utrecht (NL) 17,031 27 31 17 (54.8) 13 1 14 3 0 
Cambridge (UK) 30,440 75 622 416 (66.9) 213 70 307* 18 91 
Heidelberg (DE) 25,538 25 162 77 (47.5) 50 12 62 12 3 
San Sebastian (ES) 8,417 8 46 39 (84.8) 31 1 32 6 1 
Navarra (ES) 8,084 8 41 41 (100.0) 18 3 21 13 7 
Murcia (ES) 8,516 7 99 99 (100.0) 52 1 53 24 22 
Turin (IT) 10,587 10 143 81 (56.6) 28 1 29 44 8 
Varese (IT) 11,896 11 13 13 (100.0) 3 3 7* 6 0 
Florence (IT) 13,596 13 57 50 (87.7) 23 3 26 3 21 
Naples (IT) 5,061 4 22 22 (100.0) 13 0 13 0 9 
Greece (GR) 27,514 35 120 120 (100.0) 95 0 95 16 9 
Total  220,494 309 1,723 1,336 734 113 881 230 225 
* incident and prevalent PD cases do not total all PD cases, as there are missing data on date of diagnosis 
 
17 
 
  
Table 2: General and clinical characteristics of the PD cases, using the NeuroEPIC4PD labels 
 
 
 Definite PD Very likely PD Probable PD Possible PD All PD 
N 199 275 146 261 881 
Male (%) 77 (38.7) 164 (59.6) 73 (50.0) 144 (55.2) 458 (52.0) 
Mean age at recruitment (SD) 59.1 (8.4) 61.5 (8.0) 61.6 (6.6) 64.8 (8.1) 61.9 (8.2) 
Mean age at symptom onset (SD) 64.9 (8.1) 65.4 (9.4) 69.0 (7.1) 71.0 (8.1) 66.8 (8.3) 
Mean age at diagnosis (SD) 65.7 (7.8) 66.2 (10.2) 69.3 (7.5) 71.0 (9.2) 67.9 (9.2) 
Cardinal signs^      
 Resting tremor (%) 151 (75.9) 121 (63.0) 91 (62.3) 29 (24.8) 392 (59.9) 
 Bradykinesia (%) 192 (96.5) 147 (76.6) 118 (80.8) 43 (36.8) 500 (76.5) 
 Rigidity (%) 191 (96.0) 132 (68.8) 114 (78.1) 42 (35.9) 479 (73.2) 
 Postural instability (%) 33 (16.6) 31 (16.2) 31 (21.2) 19 (16.2) 114 (17.4) 
Treatment       
 Dopamine receptor agonists (%) 133 (66.8) 128 (46.5) 67 (45.9) 42 (16.1) 370 (42.0) 
 Levodopa (%) 177 (88.9) 163 (59.3) 114 (78.1) 79 (30.3) 533 (60.5) 
 COMT inhibitors (%) 85 (42.7) 84 (30.5) 35 (24.0) 25 (9.6) 229 (26.0) 
 MAO-B inhibitors (%) 61 (30.7) 65 (23.6) 36 (24.7) 24 (9.2) 186 (21.1) 
 Amantadine (%) 16 (8.0) 16 (5.8) 8 (5.5) 5 (1.9) 45 (5.1) 
 Antimuscarinic (%) 2 (1.0) 5 (1.8) 0 (0.0) 5 (1.9) 12 (1.4) 
 DBS -STN (%) 9 (4.5) 3 (1.1) 1 (0.9) 0 (0.0) 13 (0.3) 
 DBS-VIM (%) 1 (0.5) 1 (0.4) 0 (0.0) 0 (0.0) 2 (0.2) 
 DBS-GP (%) 1 (0.5) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.1) 
Death (%) 16 (8.0) 99 (36.0) 46 (31.5) 128 (49.0) 289 (32.8) 
^ coded as cardinal sign, i.e. symptom recorded during the first 3 years of disease; * figures do not add up to 100% as the option Not Available was possible for each of the 
questions; PIGD: Postural instability/gait disturbance; DBS: deep brain stimulation; STN: substantia nigra; VIM: ventral intermediate nucleus of the thalamus; GP: Globus Pallidus. 
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Figure legends: 
 
Figure 1: Number of expected PD cases, potential cases, cases reviewed in phase II, and ascertained PD cases by 
centre, in the NeuroEPIC4PD study 
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Figure 2: Age-specific cumulative incidence of PD by country, in men.   
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Figure 3: Age-specific cumulative incidence of PD by country, in women (y-axis is deliberately on the same scale as in Figure 2 for 
facilitating comparison).  
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Online Table 1 Demographic characteristics of the NeuroEPIC4PD cohort 
 
 
Centre  
N Men (%) Mean age (yrs) Mean years of 
follow-up 
Person years (SD) Last follow-up Deaths 
Umea (SW) 25,717 12,427 (48.3) 46.0 (10.3) 13.7 (2.7) 352,832 (432) 22/02/2009 1,391 (5.4) 
Malmo (SW) 28,097 11,062 (39.4) 58.1 (7.6) 13.9 (3.0) 390,137 (495) 31/12/2008 4,421 (15.7) 
Utrecht (NL) 17,031 0 (0.0) 57.7 (6.0) 12.9 (2.1) 220,190 (274) 01/01/2009 1,441 (8.5) 
Cambridge (UK) 30,440 13,697 (45.0) 59.4 (9.4) 13.0 (3.1) 396,149 (534) 06/03/2010 5,969 (19.6) 
Heidelberg (DE) 25,538 11,929 (46.7) 50.9 (8.1) 11.3 (2.0) 288,269 (316) 16/06/2010 1,407 (5.5) 
San Sebastian (ES) 8,417 4,158 (49.4) 49.6 (7.7) 12.5 (1.5) 105,178 (139) 17/05/2008 450 (5.4) 
Navarra (ES) 8,084 3,908 (48.3) 49.6 (7.6) 13.8 (1.7) 111,595 (152) 26/08/2009 410 (5.1) 
 Murcia (ES) 8,516 2,685 (31.5) 48.8 (8.2) 13.2 (1.5) 112,641 (137) 09/11/2008 339 (4.0) 
Turin (IT) 10,587 6,040 (57.1) 50.1 (7.7) 13.4 (2.3) 141,770 (238) 21/05/2010 497 (4.7) 
Varese (IT) 11,896 2,474 (20.8) 51.6 (8.2) 11.3 (1.8) 134,002 (193) 31/12/2006 415 (3.5) 
Florence (IT) 13,596 3,513 (25.8) 51.5 (7.7) 12.0 (1.8) 163,572 (207) 31/12/2007 438 (3.2) 
Naples (IT) 5,061 0 (0.0) 50.2 (7.7) 11.6 (1.2) 58,748 (85) 31/12/2006 140 (2.8) 
Greece (GR) 27,514 11,427 (41.5) 53.1 (12.6) 9.7 (3.1) 266,396 (513) 23/12/2009 2,155 (7.8) 
Total  220,494 83,320 (37.8) 53.1 (10.0) 12.4 (2.8) 2,741,780 (1,330) 16/06/2010 19,473 (8.8) 
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Online Table 2: Parkinson’s disease cases divided by NeuroEPIC4PD label, and parkinsonian-related disorders, by centre in the NeuroEPIC4PD 
study 
 
 
Centre  
Cases 
reviewed in 
phase II 
Definite 
PD 
Very likely PD Probable PD Possible PD Total PD MSA PSP  Vascular 
Parkinsonism  
LBD Essential tremor  PD + 
essential 
tremor  
Unclassifiable 
parkinsonism  
Umea (SW) 62 45 3 8 0 56 3 1 0 0 0 1 1 
Malmo (SW) 299 24 41 49 52 166 8 10 17 15 4 3 22 
Utrecht (NL) 17 8 5 0 1 14 1 0 0 0 1 0 1 
Cambridge (UK) 416 7 130 13 157 307 2 1 4 4 4 1 2 
Heidelberg (DE) 77 2 16 39 5 62 6 1 0 4 0 0 1 
San Sebastian (ES) 39 11 21 0 0 32 0 2 1 2 1 0 0 
Navarra (ES) 41 6 9 3 3 21 1 0 0 3 2 2 5 
Murcia (ES) 99 7 17 16 13 53 1 5 5 2 5 2 4 
Turin (IT) 81 0 10 2 17 29 2 1 2 1 6 0 32 
Varese (IT) 13 2 1 2 2 7 1 0 0 1 1 0 3 
Florence (IT) 50 11 14 1 0 26 0 1 1 0 1 0 0 
Naples (IT) 22 8 5 0 0 13 0 0 0 0 0 0 0 
Greece (GR) 120 68 3 13 11 95 1 0 4 2 5 0 4 
Total  1,336 199 275 146 261 881 26 22 34 34 30 9 75 
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Online Figure 1: Framework of the phases for case ascertainment procedures in the NeuroEPIC4PD study 
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Online Figure 2: Matrix combining the two variables amount and quality of data available and the degree of confidence of the neurologist 
expert in movement disorders reviewing the evidence, resulting in the NeuroEPIC4PD label to be attached to each diagnosis 
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Online Figure 3: Sources of information used for Phase I, by centre 
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Online Figure 4: Number of tremor-dominant, akinetic-rigid, and postural-instability/gait disturbance (PIGD) predominant forms of PD at 
onset, by NeuroEPIC4PD label. Data is not available for 14 definite PD, 146 very likely, 40 probable, and 223 possible PD. 
 
 
  
 
 
